EW (Edwards Lifesciences Corp)
Insider Trading Activity
Every open-market purchase and sale reported by EW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-31 | Andrew M. Dahl | SVP, Corporate Controller | Sell | — | — |
| 2026-08-28 | Annette Bruls | CVP, EMEACLA | Sell | — | — |
| 2026-08-26 | Wayne Markowitz | CVP, JAPAC | Sell | — | — |
| 2026-08-26 | Daveen Chopra | CVP, TMTT, Surgical & IHFM | MIXED | — | — |
| 2026-08-11 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-07-30 | Wayne Markowitz | CVP, JAPAC | Sell | — | — |
| 2026-07-28 | Wayne Markowitz | CVP, JAPAC | MIXED | — | — |
| 2026-07-27 | Bernard J Zovighian | CEO | MIXED | — | — |
| 2026-07-13 | Annette Bruls | CVP, EMEACLA | F | — | — |
| 2026-07-10 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-07-10 | Theodora Mistras | CVP, Chief Financial Officer | A | — | — |
| 2026-07-07 | Daniel J. Lippis | CVP, TAVR | F | — | — |
| 2026-06-17 | Bernard J Zovighian | CEO | Sell | — | — |
| 2026-05-29 | Andrew M. Dahl | SVP, Corporate Controller | Sell | — | — |
| 2026-05-27 | DONALD E BOBO JR | CVP,Strategy/Corp Development | Sell | — | — |
| 2026-05-22 | Daveen Chopra | CVP, TMTT & Surgical | Sell | — | — |
| 2026-05-18 | DONALD E BOBO JR | CVP,Strategy/Corp Development | Sell | — | — |
| 2026-05-18 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-05-12 | Daveen Chopra | CVP, TMTT & Surgical | MIXED | — | — |
| 2026-05-12 | DONALD E BOBO JR | CVP,Strategy/Corp Development | MIXED | — | — |
| 2026-05-12 | Bernard J Zovighian | CEO | MIXED | — | — |
| 2026-05-11 | Daniel J. Lippis | CVP, TAVR | F | — | — |
| 2026-05-11 | Bernard J Zovighian | CEO | MIXED | — | — |
| 2026-05-11 | Wayne Markowitz | CVP, JAPAC | MIXED | — | — |
| 2026-05-11 | Scott B. Ullem | CVP, Chief Financial Officer | MIXED | — | — |
| 2026-05-08 | Annette Bruls | CVP, EMEACLA | MIXED | — | — |
| 2026-05-08 | Daveen Chopra | CVP, TMTT & Surgical | MIXED | — | — |
| 2026-05-08 | Andrew M. Dahl | SVP, Corporate Controller | MIXED | — | — |
| 2026-05-08 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-05-08 | Leslie C. Davis | Director | A | — | — |
| 2026-05-08 | Scott B. Ullem | CVP, Chief Financial Officer | F | — | — |
| 2026-05-08 | DONALD E BOBO JR | CVP,Strategy/Corp Development | MIXED | — | — |
| 2026-05-08 | David T Feinberg | Director | A | — | — |
| 2026-05-08 | KIERAN GALLAHUE | Director | A | — | — |
| 2026-05-08 | HEISZ LESLIE STONE | Director | A | — | — |
| 2026-05-08 | PAUL A LAVIOLETTE | Director | A | — | — |
| 2026-05-08 | STEVEN R LORANGER | Director | A | — | — |
| 2026-05-08 | Ramona Sequeira | Director | A | — | — |
| 2026-05-08 | NICHOLAS J VALERIANI | Director | A | — | — |
| 2026-05-05 | Bernard J Zovighian | CEO | MIXED | — | — |
| 2026-05-05 | Scott B. Ullem | CVP, Chief Financial Officer | MIXED | — | — |
| 2026-05-04 | DONALD E BOBO JR | CVP,Strategy/Corp Development | F | — | — |
| 2026-05-04 | Daveen Chopra | CVP, TMTT & Surgical | F | — | — |
| 2026-05-04 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-04-09 | Scott B. Ullem | CVP, Chief Financial Officer | MIXED | — | — |
| 2026-04-06 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-04-02 | DONALD E BOBO JR | CVP,Strategy/Corp Development | MIXED | — | — |
| 2026-03-11 | Daniel J. Lippis | CVP, TAVR | MIXED | — | — |
| 2026-03-11 | Scott B. Ullem | CVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | DONALD E BOBO JR | CVP,Strategy/Corp Development | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,060,005 | — |
| — | CVP, Strategy & Corp Dev | 610,602 | — |
| — | Director | 494,406 | — |
| — | CVP | 466,092 | — |
| — | CVP, Europe | 417,411 | — |
| — | CVP, Public Affairs/Special Co | 336,426 | — |
| — | Director | 327,996 | — |
| — | CVP, Chief Financial Officer | 313,058 | — |
| — | Director | 307,440 | — |
| — | Director | 303,378 | — |
| — | CVP, Critical Care / Vascular | 295,248 | — |
| — | Director | 289,596 | — |
| — | Director | 280,197 | — |
| — | CVP & Pres., Global Ops | 267,444 | — |
| — | CVP, CFO | 258,282 | — |
| — | Global President TAVR & Surg | 207,048 | — |
| — | Director | 192,372 | — |
| — | CVP, Critical Care & Vascular | 186,924 | — |
| — | CVP, EMEACLA and JAPAC | 184,685 | — |
| — | CVP, North America | 183,600 | — |
| — | CVP,Strategy/Corp Development | 121,409 | — |
| — | CEO | 107,760 | — |
| — | CVP, Japan & Intercontinental | 99,381 | — |
| — | Director | 94,440 | — |
| — | CVP, Chief Financial Officer | 87,595 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EW quote page; the site-wide leaderboard is on the insider transactions hub.